STRATA Skin Sciences Surpasses 100 Domestic Installations of TheraClear®X Devices as of March 31, 2024
May 14 2024 - 8:15AM
STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ:
SSKN), a medical technology company dedicated to developing,
commercializing, and marketing innovative products for the
treatment of dermatologic conditions, announces its installed base
of TheraClear®X devices surpassed 100 at the end of the first
quarter of 2024.
As Strata is focused on expanding its
TheraClear®X placements within existing XTRAC® partner clinics, a
number of the device placements are with private equity-backed
dermatology clinics, including the California Skin Institute and
Aqua Dermatology, and other strategic accounts, including
Pennsylvania Dermatology Partners, which has 35 clinics in its
group practice. Additionally, one device placement was a comeback
win with Palo Alto Medical Foundation.
The 48 individual private equity backed groups
of clinical dermatology clinics STRATA is currently partnered with
have a total of 2,482 locations, in which Strata has deployed 386
XTRAC® and 62 TheraClear®X devices.
“We continue to grow our domestic installed base
of TheraClear®X devices quarter by quarter,” commented STRATA CEO
Dr. Dolev Rafaeli. “As with our much more established XTRAC®
offering, dermatologists recognize the value of our comprehensive
program in treating acne, which is the most common skin condition
in dermatology. TheraClear®X addresses many of the limitations of
existing acne therapies, and its effectiveness is often visible
after just a few treatments. Its unique photo pneumatic technology
combines vacuum with pulsed broadband light that works both
mechanically and thermally on the active acne lesion. With
TheraClear®X, dermatologists now have a reimbursable option to
treat acne, improving the economics for their practice. We look
forward to working closely with our customers/partners to continue
to increase our domestic install base and reporting on those
outcomes in the coming quarters.”
About STRATA Skin Sciences, Inc.STRATA Skin
Sciences is a medical technology company dedicated to developing,
commercializing, and marketing innovative products for the
in-office treatment of various dermatologic conditions, such as
psoriasis, vitiligo, and acne. Its products include the
XTRAC® excimer laser, VTRAC® lamp systems, and the
TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting technologies in the U.S.
through its unique Partnership Program. STRATA’s popular
partnership approach includes a fee per treatment cost structure
versus an equipment purchase, installation and use of the device,
on-site training for practice personnel, service and maintenance of
the equipment, dedicated account and customer service associates,
and co-op advertising support to help raise awareness and promote
the program within the practice.
Safe HarborThis press release includes
"forward-looking statements" within the meaning of the Securities
Litigation Reform Act of 1995. These statements include but are not
limited to the Company’s plans, objectives, expectations and
intentions and may contain words such as “will,” “may,” “seeks,”
and “expects,” that suggest future events or trends. These
statements, the Company’s ability to launch and sell products
recently acquired or to be developed in the future, the Company’s
ability to develop social media marketing campaigns, direct to
consumer marketing campaigns, and the Company’s ability to build a
leading franchise in dermatology and aesthetics, are based on the
Company’s current expectations and are inherently subject to
significant uncertainties and changes in circumstances. Actual
results may differ materially from the Company’s expectations due
to financial, economic, business, competitive, market, regulatory,
adverse market conditions labor supply shortages, or supply chain
interruptions resulting from fiscal, political factors,
international conflicts, responses, or conditions affecting the
Company, the medical device industry and our customers and patients
in general, as well as more specific risks and uncertainties set
forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given
such uncertainties, any or all these forward-looking statements may
prove to be incorrect or unreliable. The statements in this press
release are made as of the date of this press release, even if
subsequently made available by the Company on its website or
otherwise. The Company does not undertake any obligation to update
or revise these statements to reflect events or circumstances
occurring after the date of this press release. The Company urges
investors to carefully review its SEC disclosures available
at www.sec.gov and www.strataskinsciences.com.
Investor Contact:CORE
IR516-222-2560IR@strataskin.com
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Apr 2024 to May 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From May 2023 to May 2024